EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease

European Journal of Neurology

Volumn 22, Issue 6, 2015, Pages 889-898

  Schmidt, R ^a   Hofer, E ^a   Bouwman, F H ^b   Buerger, K ^c   Cordonnier, C ^d   Fladby, T ^e   Galimberti, D ^f   Georges, J ^g   Heneka, M T ^h   Hort, J ^i,j   Laczo J ^i,j   Molinuevo, J L ^k   O'Brien, J T ^l   Religa, D ^m,n   Scheltens, P ^b   Schott, J M ^o   Sorbi, S ^p  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIV LILLE   (France)

^e AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF MILAN   (Italy)

^g Alzheimer Europe ^*  (Luxembourg)

^h GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^k INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^o UNIVERSITY COLLEGE LONDON   (United Kingdom)

^p UNIVERSITY OF FLORENCE   (Italy)

more..

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Dementia; EFNS ENS Guidelines; Grading of Recommendations Assessment, Development and Evaluation; Memantine; Meta analysis; Treatment

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE; AMINO ACID RECEPTOR BLOCKING AGENT;

ALZHEIMER DISEASE; ARTICLE; ATTRIBUTABLE RISK; CLINICAL PRACTICE; COGNITION; DAILY LIFE ACTIVITY; DISEASE SEVERITY; FOLLOW UP; HUMAN; META ANALYSIS; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; DRUG COMBINATION; PRACTICE GUIDELINE;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; PRACTICE GUIDELINES AS TOPIC;

EID: 84928311843     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12707     Document Type: Article

References (31)

1. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res 2013; 24: 358-369.
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006: CD005593.
3. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006: CD003154.
4. EMEA Committee for Medicinal Products for Human. Plenary Meeting Monthly Report. http://www.emea.europe.eu/pdfs/human/press/pr/36234805en.pdf (accessed 18/03/2014).
5. Patel L, Grossberg GT. Combination therapy for Alzheimer's disease. Drugs Aging 2011; 28: 539-546.
6. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-324.
7. van Dyck CH, Schmitt FA, Olin JT, Memantine MEMMDSG. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry 2006; 14: 428-437.
8. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22: 209-221.
9. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Memantine MEMMDSG. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008; 5: 83-89.
10. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80: 600-607.
11. Choi SH, Park KW, Na DL, et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin 2011; 27: 1375-1383.
12. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366: 893-903.
13. Wilkinson D, Fox NC, Barkhof F, Phul R, Lemming O, Scheltens P. Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. J Alzheimers Dis 2012; 29: 459-469.
14. Cummings JL, Schneider E, Tariot PN, Graham SM, Memantine MEMMDSG. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006; 67: 57-63.
15. Feldman HH, Schmitt FA, Olin JT, Memantine MEMMDSG Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 2006; 20: 263-268.
16. (NICE) NIfCE. Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease. NICE Technology Appraisal Guidance 217 (Review of NICE Technology Appraisal Guidance 111). http://publications.nice.org.uk/donepezil-galantamine-rivastigmine-and-memantine-for-the-treatment-of-alzheimers-disease-ta217/guidance (accessed 18/03/2014).
17. Herrmann N, Lanctot KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther 2013; 5: S5.
18. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open 2012; 2: e000917.
19. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926.
20. Leone MA, Brainin M, Boon P, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2012. Eur J Neurol 2013; 20: 410-419.
21. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011; 64: 395-400.
22. The Cochrane Dementia and Cognitive Improvement Group. ALOIS: a comprehensive register of dementia studies. http://www.medicine.ox.ac.uk/alois/ (accessed 02/06/2014).
23. Grossberg GT, Manes F, Allegri RF, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs 2013; 27: 469-478.
24. Schneider LS, Insel PS, Weiner MW. Alzheimer's disease neuroimaging I. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol 2011; 68: 58-66.
25. The Cochrane Collaboration. Review Manager (RevMan). 5.2., 2012.
26. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383-394.
27. Brozek J, Oxman A, Schünemann H. GRADEpro. 3.2 for Windows, 2008.
28. Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20-27.
29. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157: 4-15.
30. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
31. Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002; 59: 1721-1729.